Biosimilars

Latest News

nAMD patients successfully switch from aflibercept to biosimilar ranibizumab
nAMD patients successfully switch from aflibercept to biosimilar ranibizumab

September 13th 2024

Visual acuity and macular anatomy were maintained, with some changes in fluid management.

Biosimilars for retinal diseases: The long and winding road into clinical practice
Biosimilars for retinal diseases: The long and winding road into clinical practice

September 12th 2024

Lupin announces successful completion of phase 3 trials for LUBT010
Lupin announces successful completion of phase 3 trials for LUBT010

August 7th 2024

FDA approves Formycon’s biosimilar to Eylea, aflibercept-mrbb (Ahzantive)
FDA approves Formycon’s biosimilar to Eylea, aflibercept-mrbb (Ahzantive)

July 2nd 2024

Latest FDA biosimilar approvals ushering in more treatment options
Latest FDA biosimilar approvals ushering in more treatment options

May 29th 2024

Latest CME Events & Activities

Going to AAO? Join Us for Free CME In-Person or Virtually

October 18-19, 2024

Register Now!

(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action

View More

(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action

View More

Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)

View More

Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)

View More

Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data

View More

Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME

View More

(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon

View More

(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon

View More

(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment

View More

(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment

View More

(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape

View More

(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape

View More

(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium

View More

Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)

View More

Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)

View More

SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management

View More

EnVision Summit

February 14-17, 2025

Register Now!

Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care

View More

Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)

View More

Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)

View More

Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)

View More

Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)

View More

Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)

View More

Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)

View More

Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)

View More

Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)

View More

Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)

View More

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)

View More

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)

View More

More News

© 2024 MJH Life Sciences

All rights reserved.